STOCK TITAN

Moleculin Biotech, Inc. - MBRX STOCK NEWS

Welcome to our dedicated page for Moleculin Biotech news (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotech stock.

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses. Known for its innovative drug candidates, Moleculin's pipeline aims to address significant unmet medical needs. The company's flagship product, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance mechanisms and minimize cardiotoxicity. Annamycin is currently in Phase II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Moleculin's research is rooted in discoveries from the acclaimed M.D. Anderson Cancer Center. In addition to Annamycin, the company is developing WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other malignancies. WP1066 aims to inhibit oncogenic transcription factors such as p-STAT3 while stimulating the patient's immune response.

Another promising candidate, WP1220, an analog of WP1066, is being developed for the topical treatment of cutaneous T-cell lymphoma. The company also has a robust antimetabolite portfolio, including WP1122, which is being investigated for its potential in treating both viral infections and various cancers.

Recent achievements highlight Moleculin's significant progress. Positive preclinical data for Annamycin were presented at the American Association for Cancer Research (AACR) Annual Meeting, demonstrating its non-cardiotoxic properties and potent inhibition of topoisomerase II-beta. Annamycin has also received Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA) for AML, providing Moleculin with extended market exclusivity and reduced regulatory fees.

Financially, Moleculin maintains a solid footing with sufficient capital to support its ongoing clinical trials and future projects. The company's recent financial report indicates a strategic focus on advancing its clinical and regulatory strategies. With multiple patents issued and pending, Moleculin continues to strengthen its intellectual property portfolio, positioning itself favorably for potential partnerships and market expansion.

Collaborations with leading institutions such as Northwestern University and funding from entities like the National Institutes of Health (NIH) underscore the robust support for Moleculin's initiatives. The company's innovative approach and commitment to addressing challenging medical conditions make it a noteworthy entity in the biopharmaceutical landscape.

For more details, please visit Moleculin's website and connect on Twitter, LinkedIn, and Facebook.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
conferences
-
Rhea-AI Summary
Moleculin Biotech, Inc. announced that its President and CEO, Walter Klemp, and its CFO, Jonathan Foster, will present at the Healthcare Virtual Conference Part II on June 21st. The conference will focus on key data-driven events in the healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.77%
Tags
none
-
Rhea-AI Summary
Moleculin Biotech reports positive clinical and operational progress, sufficient capital to fund operations until Q3 2024. Conference call and webcast scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
conferences earnings
-
-
Rhea-AI Summary

Moleculin Biotech, Inc. (Nasdaq: MBRX) presented positive preclinical data for Annamycin, a next-generation anthracycline, at the American Association for Cancer Research (AACR) Annual Meeting 2023. The research showcased Annamycin's enhanced liver accumulation, significantly exceeding doxorubicin's uptake, and demonstrated high antitumor efficacy in liver cancer models. Key findings included a six-fold increase in liver accumulation compared to doxorubicin, substantial inhibition of tumor growth, and improved survival rates in various models. Annamycin is currently under evaluation in clinical trials targeting soft tissue sarcoma lung metastases and acute myeloid leukemia. These promising results bolster future studies and potential for Annamycin as a viable treatment option for hard-to-treat tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.34%
Tags
none
Rhea-AI Summary

Moleculin Biotech (NASDAQ: MBRX) reported its financial results for 2022, showing a net loss of $29.0 million, up from $6.7 million in 2021. R&D expenses increased to $19.0 million, driven by heightened clinical trial activities. The company has sufficient cash, totaling $43.1 million, to fund operations into the third quarter of 2024. Recent highlights include positive data from Annamycin's trials, an 80% overall response rate for refractory AML, and Fast Track Designation from the FDA for WP1122. A conference call to discuss results will be held on March 23, 2023, at 8:30 AM ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.45%
Tags

FAQ

What is the current stock price of Moleculin Biotech (MBRX)?

The current stock price of Moleculin Biotech (MBRX) is $1.82 as of December 24, 2024.

What is the market cap of Moleculin Biotech (MBRX)?

The market cap of Moleculin Biotech (MBRX) is approximately 5.8M.

What is Moleculin Biotech's lead product candidate?

Moleculin's lead product candidate is Annamycin, a next-generation anthracycline designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

What are the key focus areas of Moleculin Biotech's research?

Moleculin Biotech focuses on developing therapies for hard-to-treat tumors and viruses, including drug candidates like Annamycin for AML and STS, and WP1066 for brain tumors and pancreatic cancer.

What recent achievements has Moleculin Biotech reported?

Moleculin has presented positive preclinical data on Annamycin's non-cardiotoxic properties, received Orphan Drug Designation for AML from both the FDA and EMA, and secured new patents for Annamycin.

How is Moleculin Biotech financially positioned?

Moleculin maintains sufficient capital to support its ongoing Phase IIB/2 clinical programs and additional future projects, as indicated by its latest financial report.

What collaborations is Moleculin Biotech involved in?

Moleculin collaborates with top institutions like Northwestern University and receives funding from entities such as the National Institutes of Health (NIH).

What is the significance of Annamycin's Orphan Drug Designation?

Orphan Drug Designation grants Moleculin benefits like reduced regulatory fees and market exclusivity for Annamycin, supporting its development for rare conditions like AML.

What is WP1066, and what does it target?

WP1066 is an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other malignancies. It aims to inhibit oncogenic transcription factors and stimulate the immune response.

What is WP1220 used for?

WP1220 is an analog of WP1066, being developed for the topical treatment of cutaneous T-cell lymphoma.

What is the potential of WP1122?

WP1122 is part of Moleculin's antimetabolite portfolio, currently being explored for treatment of viral infections and various cancers, including brain and pancreatic tumors.

Where can I find more information about Moleculin Biotech?

For more information, visit Moleculin's website at www.moleculin.com and follow them on social media platforms like Twitter, LinkedIn, and Facebook.

Moleculin Biotech, Inc.

Nasdaq:MBRX

MBRX Rankings

MBRX Stock Data

5.81M
3.09M
3.34%
15.34%
1.8%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HOUSTON